This article has Open Peer Review reports available.
A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): A case report
© Schroeder et al; licensee BioMed Central Ltd. 2008
Received: 11 June 2008
Accepted: 30 September 2008
Published: 30 September 2008
Glycogen storage disease type Ib is an autosomal recessive transmitted disorder of glycogen metabolism caused by mutations in the glucose-6-phosphate translocase gene on chromosome 11q23 and leads to disturbed glycogenolysis as well as gluconeogenesis. Besides hepatomegaly, growth retardation, hypoglycemia, hyperlactatemia, hyperuricemia and hyperlipidemia, patients suffer from neutropenia associated with functional defects predisposing for severe infections. In order to attenuate these complications, long-term treatment with granulocyte colony-stimulating factor is common but this is associated with an increased risk for acute myeloid leukemia or myelodysplastic syndromes in patients with inherited bone marrow failures such as severe congenital neutropenia. Onset of these myeloid malignancies is linked to cytogenetic aberrations involving chromosome 7. In addition, granulocyte colony-stimulating factor is known to stimulate proliferation of monosomy 7 cells in vitro. To our knowledge, we report for the first time a case report of a patient with glycogen storage disease type Ib, who developed acute myeloid leukemia with a classical monosomy 7 and acute myeloid leukemia-associated translocation t(3;8)(q26;q24) after 14 years of continuous treatment with granulocyte colony-stimulating factor.
A 28-year-old Turkish man with glycogen storage disease type Ib was admitted to our department because of dyspnea and increasing fatigue. He also presented with gum bleeding, bone pain in his legs, night sweats, recurrent episodes of fever with temperatures up to 39°C and hepatosplenomegaly.
A blood count taken on the day of admission showed pancytopenia and a differential count displayed 30% blasts. A bone marrow biopsy was taken which showed a hypercellular marrow with dysplastic features of all three cell lines, while blast count was 20%. Classical cytogenetic analyses as well as fluorescence in situ hybridization showed a monosomy 7 with a translocation t(3;8)(q26;q24). Based on these findings, the diagnosis of acute myeloid leukemia was made.
Our observations suggest that bone marrow examinations including cytogenetic analysis should be carried out on a regular basis in patients with glycogen storage disease type Ib who are on long-term treatment with granulocyte colony-stimulating factor for severe neutropenia, since this treatment might also contribute to an increased risk for acute myeloid leukemia or myelodysplastic syndromes.
Glycogen storage disease type Ib (GSD-Ib), one of over 12 inherited metabolic disorders of glycogen metabolism, is an autosomal recessive disease caused by mutations in the glucose-6-phosphate translocase (G6PT) gene on chromosome 11q23. As a result of the G6PT deficiency, glycogenolysis as well as gluconeogenesis is disturbed. Patients suffer from hepatomegaly, growth retardation, hypoglycemia, hyperlactatemia, hyperuricemia and hyperlipidemia. The disease is further characterized by neutropenia associated with functional defects predisposing for severe infections including perioral and perianal ulcers as well as inflammatory bowel disease. In order to attenuate these complications, long-term treatment with granulocyte colony-stimulating factor (G-CSF) is common .
We report the case of a 28-year-old Turkish man with a GSD-Ib who received treatment with G-CSF for 14 years because of disease-associated neutropenia. He has now developed acute myeloid leukemia (AML) with monosomy 7 and translocation t(3;8)(q26;q24). Admission to our hospital was required because of dyspnea and increasing fatigue. He also presented with gum bleeding, bone pain in his legs, night sweats, and recurrent episodes of fever with temperatures up to 39°C.
At the age of 1 year, a liver biopsy including enzyme function tests, which was performed because of hepatomegaly, recurrent hypoglycemia, growth retardation and bacterial infections of the upper respiratory system, confirmed the diagnosis GSD-Ib. As accessible in 1999, a mutational analysis of peripheral blood cells showed a homozygous mutation of exon 8 of the G6PT-locus (GPTL c.1211 del CT/c.1211 del CT) confirming this diagnosis. In the past, he had experienced recurrent episodes of hypoglycemia and hyperlactatemia associated with severe metabolic decompensations often requiring hospitalization. In order to prevent these metabolic disturbances, a special diet consisting of regular, carbohydrate-rich meals every 2 hours and ingestion of uncooked cornstarch twice per night was necessary. Because of relapsing oral and perianal aphthous ulcers as a result of severe neutropenia and neutrophilic dysfunction as indicated by a decreased deoxyglucose uptake, he received either filgrastim or lenograstim from the age of 15 years at different dose levels. In detail, cumulative duration of G-CSF therapy was 12.84 years and time-averaged dose was 2.83 μg/kg/day, leading to a total cumulative dose 13,729 μg/kg. An increase in white blood cell (WBC) count from baseline values of 3200/μl with a median of 14% neutrophils to a WBC count of 4245/μl with a median of 38% neutrophils could be achieved. The rise in neutrophil counts led to a substantial reduction in infectious complications. Bone marrow examinations were performed four times since the beginning of G-CSF treatment. The last examination was carried out at the age of 22 years showing no signs of leukemic transformation.
The patient is retarded in growth with a size of 160 cm and a body weight of 50 kg. The color of his skin is pale and he has hardly any secondary body hair. We found a few aphthous ulcers scattered in the oral cavity and mucosa bleeding. As confirmed by abdominal sonography, the patient had hepatosplenomegaly (liver 124 mm craniocaudal diameter × 148 mm dorsoventral diameter in medioclavicular line, spleen length 138 mm × depth 57 mm). Blood count taken at the day of admission showed pancytopenia with a WBC count of 2.000/μl, reduced hemoglobin of 4.2 g/dl with normal erythrocyte indices and a platelet count of 71 × 103/μl. Differential count was as follows: 62% lymphocytes, 4% monocytes, 4% mature neutrophilic granulocytes and 30% blasts. A first bone marrow biopsy was taken showing a hypercellular marrow with dysplastic features of all three cell lines, while blast count was 20%. This result was confirmed by flow cytometry analysis with 30% CD34 positive cells.
In the light of the increased risk profile of this patient due to his metabolic disorder and the low response rate to conventional chemotherapy of patients with chromosome 7 abnormalities, we administered a first course of DNA methyl transferase inhibitor 5-azacytidine (151 mg absolute subcutaneously daily for 5 days). This decision was made because chromosome 7 alterations predict response to treatment with this drug in patients with myelodysplastic syndromes (MDS) or AML . At the time of writing this report, 100 days after the beginning of the first course of the epigenetic therapy, the patient is still alive. Transfusion-dependent pancytopenia persists, which is in line with prior studies showing a response to 5-azacytidine after 3 or 4 cycles . Administration of a second course of 5-azacytidine was avoided by infectious complications until now. Because patients with chromosome 7 abnormalities have a poor prognosis, the use of myeloablative conditioning therapy allogeneic blood stem cell transplantation with his Human Leukocyte Antigen (HLA) identical twin sister is envisaged for the patient.
As in our patient, neutropenia and neutrophilic dysfunction are characteristic findings in patients with GSD-Ib leading to an increased risk of infectious diseases. Some of the molecular mechanisms underlying the neutrophilic dysfunctions in patients with GSD-Ib were unraveled by Kim et al. . For instance, neutrophil granulocytes exhibit impaired respiratory burst as well as impaired chemotaxis and calcium flux. The neutrophils also have an increased preponderance for apoptosis which contributes to the development of neutropenia. The major reason for these disturbances is the G6PT-defiency in the endoplasmic reticulum (ER) membrane of neutrophils resulting in a lack of glucose and increased oxidative stress . The results of our genome-wide expression data on CD34+ cells from bone marrow of normal donors (data not shown) suggest that G6PT is normally expressed in hematopoietic stem and progenitor cells. A G6PT-deficiency in the CD34+ progenitor might therefore be of functional relevance, in particular for the regular differentiation along the myeloid pathway while erythropoiesis and thrombopoiesis are not affected.
There are two case histories in the literature reporting on patients with GSD-Ib who had developed AML. One of them received G-CSF over a period of 6 years, while the other did not receive the growth factor. Cytogenetic analysis in the patient being treated with G-CSF showed a normal 46 XX karyotype in 3 cells and a 47 XX +10 karyotype in 1 cell [4, 5]. Thus, considering the low incidence of GSD-1b, neither an increased intrinsic risk for AML nor an association between G-CSF treatment and evolution of myeloid neoplasms has been noted so far .
With regard to neutropenia, we will place this case in the context of other inherited bone marrow failures with isolated neutropenias such as severe congenital neutropenia (SCN) or Shwachman-Diamond syndrome (SDS). These diseases are associated with an enhanced risk for AML or MDS . In addition to this intrinsic risk, the likelihood of developing myeloid neoplasms may also increase as a result of long-term treatment with G-CSF as shown by the data from the French Severe Chronic Neutropenia Study Group and the Severe Chronic Neutropenia International Registry [8, 9]. Onset of AML or MDS in these patients is linked to cytogenetic aberrations involving chromosome 7 in up to 76% of patients with SCN and 66% of patients with SDS, respectively. Long-term treatment with G-CSF is also associated with evolution of MDS in patients with aplastic anemia involving monosomy 7 in up to 58% of the patients [6, 7]. In the light of these findings, it is interesting to note that G-CSF is known to stimulate proliferation of monosomy 7 cells in vitro .
With regard to GSD-Ib, Donadieu et al. reported on a survey of 15 patients who were treated with G-CSF because of disease-related neutropenia . In this context, it is worth noting that in our patient, the total cumulative duration of G-CSF therapy (12.84 years) was much longer than in the group reported by Donadieu et al. (median 2.8 years, range 0.1 to 8.8 years) whereas the time-averaged dose and total cumulative dose were comparable. Within this group of patients, there was no case of AML and no observations with regard to clonogenic evolution or structural or numeric aberrations of chromosome 7 .
Interestingly in our patient, at the age of 22 years, a cytogenetic analysis of bone marrow cells showed a monosomy 7 in 4.8% of the metaphases. This proportion was estimated under cut-off and considered as pathologically irrelevant. In the light of the actual finding with 78.5% of the metaphases bearing the monosomy 7, we conclude that the treatment with G-CSF might have contributed to the gradual expansion of the monosomy 7 clone over time. This view is supported by the finding of the translocation t(3;8)(q26;24) which had not been found on the occasion of the examination at the age of 22 years. This reciprocal translocation is known to lead to an aberrant expression of the proto-oncogene EVI1 and has been implicated to be a pathophysically relevant aberration for the development of an AML . Thus, it might be postulated that, during the expansion of the hematopoietic stem cell clone bearing the monosomy 7 favored by continuous stimulation with G-CSF, the additional occurrence of the translocation t(3;8)(q26;24) was an important step for leukemogenesis.
As a result of our observations, we suggest that bone marrow examinations including cytogenetic analysis should be carried out on a regular basis in patients with GSD-Ib who are on long-term treatment with G-CSF for severe neutropenia, since G-CSF might also contribute to the development of myeloid malignancies in these patients.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Ozen H: Glycogen storage diseases: new perspectives. World J Gastroenterol. 2007, 13 (18): 2541-2553.View ArticlePubMedPubMed CentralGoogle Scholar
- Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, Pomplun S, Thomas NS, Mufti GJ: CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007, 21 (9): 1937-1944. 10.1038/sj.leu.2404796.View ArticlePubMedGoogle Scholar
- Kim SY, Jun HS, Mead PA, Mansfield BC, Chou JY: Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib. Blood. 2008, 111 (12): 5704-11. 10.1182/blood-2007-12-129114.View ArticlePubMedPubMed CentralGoogle Scholar
- Pinsk M, Burzynski J, Yhap M, Fraser RB, Cummings B, Ste-Marie M: Acute myelogenous leukemia and glycogen storage disease 1b. J Pediatr Hematol Oncol. 2002, 24 (9): 756-758. 10.1097/00043426-200212000-00015.View ArticlePubMedGoogle Scholar
- Simmons PJ, Smithson WA, Gronert WA, Haymond MW: Acute myelogenous leukaemia and malignant hyperthermia in a patient with type 1b glycogen storage disease. J Pediatr. 1984, 105 (3): 428-431. 10.1016/S0022-3476(84)80020-7.View ArticlePubMedGoogle Scholar
- Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Benett CL: Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety consideration from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007, 40 (3): 185-192. 10.1038/sj.bmt.1705722.View ArticlePubMedGoogle Scholar
- Alter BP: Diagnosis, genetics and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program. 2007, 29-39.Google Scholar
- Donadieu J, Leblanc T, Bader Meunier B, Barkaoui M, Fenneteau O, Bertrand Y, Maier-Redelsperger M, Micheau M, Stephan JL, Phillipe N, Bordigoni P, Babin-Boilletot A, Bensaid P, Manel AM, Vilmer E, Thuret I, Blanche S, Gluckman E, Fischer A, Mechinaud F, Joly B, Lamy T, Hermine O, Cassinat B, Bellanné-Chantelot C, Chomienne C, French Severe Chronic Neutropenia Study Group: Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica. 2005, 90 (1): 45-53.PubMedGoogle Scholar
- Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Fier C, Freedman M, Kannourakis G, Kinsey S, Schwinzer B, Zeidler C, Welte K, Dale DC, Severe Chronic Neutropenia International Registry: The incidence of leukaemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006, 107 (12): 4628-4635. 10.1182/blood-2005-11-4370.View ArticlePubMedPubMed CentralGoogle Scholar
- Sloand EM, Yong AS, Ramkissoon S, Solomou E, Bruno TC, Kim S, Fuhrer M, Kajigaya S, Barrett AJ, Young NS: Granulocyte-colony stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci USA. 2006, 103 (39): 14483-14488. 10.1073/pnas.0605245103.View ArticlePubMedPubMed CentralGoogle Scholar
- Lennon PA, Abruzzo LV, Medeiros LJ, Cromwell C, Zhang X, Yin CC, Kornblau SM, Konopieva M, Lin P: Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24). Cancer Genet Cytogenet. 2007, 177 (1): 37-42. 10.1016/j.cancergencyto.2007.05.007.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.